查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597295

內分泌檢查的全球市場的評估:檢驗各類型，各技術，各終端用戶，各地區，機會，預測(2017年～2031年)

Endocrine Testing Market Assessment, By Test Type, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 240 Pages | 商品交期: 3-5個工作天內

價格

全球內分泌檢查的市場規模，被預測從2023年的130億3,000萬美元2031年達到244億2,000萬美元，2024年～2031年的預測期間年複合成長率8.17％的成長被預料。支撐市場成長，是內分泌疾病的由於罹患率的上升，預防醫療的認識的高漲，市場參與企業的功能和使患者的便利性提高了的產品的銷售的增加。2023年8月，美國食品藥物管理局(FDA)Mira Fertility Ovum 作為追蹤尿中的濾泡促素(FSH)層級的OTC工具列表了Wand。這個wand，能生殖能力的評估，更年期的預測，排卵預測的支援轉動，提供研究室正確的FSH層級。

內分泌檢查，對為了特別指定內分泌系的異常和不平衡，管理生殖問題，糖尿病，甲狀腺疾病等的健康狀態早期發現的荷爾蒙層級的評估不可缺少。被預測由於為了強化這些的檢驗的點閱存取和可得性的醫療部門的投資的增加，對市場擴大帶來Plus的影響。

由於為了提高對再加上一般居民的內分泌疾病的認識的高漲，及內分泌檢查的可及性的各種各樣的醫療機關的配合措施的增加，帶來著對市場有利的成長機會。複數的醫療機關和政府機關，糖尿病和甲狀腺疾病發病的風險越發用力高(貴)的族群的定期診察。另一方面，一般居民為了從健康意識的高漲，早期發現潛在的健康問題尋求定期性的健康檢查。對再加上預防醫療的轉移，也促進著全世界的各種地區的內分泌檢查的需求。

本報告提供全球內分泌檢查市場相關調查分析，市場規模與預測，市場動態，提供著主要企業的形勢等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球內分泌檢查市場預測(2017年～2031年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 檢驗各類型
    • 各技術
    • 各終端用戶
    • 各地區
    • 市場佔有率分析:各企業(金額)(前五名公司和其他 - 2023年)
  • 市場地圖分析(2023年)
    • 檢驗各類型
    • 各技術
    • 各終端用戶
    • 各地區

第5章 北美的內分泌檢查市場預測(2017年～2031年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 檢驗各類型
    • 各技術
    • 各終端用戶
    • 佔有率:各國
  • 各國的市場評估
    • 美國的內分泌檢查市場預測(2017年～2031年)
    • 加拿大
    • 墨西哥

第6章 歐洲的內分泌檢查市場預測(2017年～2031年)

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 波蘭

第7章 亞太地區的內分泌檢查市場預測(2017年～2031年)

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章 南美的內分泌檢查市場預測(2017年～2031年)

  • 巴西
  • 阿根廷

第9章 中東·非洲的內分泌檢查市場預測(2017年～2031年)

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 以色列

第10章 供需分析

第11章 價值鏈分析

第12章 波特的五力分析

第13章 大環境分析

第14章 價格分析

第15章 市場動態

  • 推動市場要素
  • 市場課題

第16章 市場趨勢與發展

第17章 法規結構和革新

  • 臨床試驗
  • 法規當局的認證

第18章 專利形勢

第19章 案例研究

第20章 競爭情形

  • 市場領導者前五名公司的競爭矩陣
  • 前五名公司的SWOT分析
  • 主要企業前十大企業的形勢
    • Abbott Laboratories
    • bioMerieux SA
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • AB Sciex Pte. Ltd.
    • DiaSorin S.p.A.
    • Quest Diagnostics Incorporated
    • Danaher Corporation

第21章 策略性推薦

第22章 本公司相關資料，免責聲明

Product Code: MX12292

Global endocrine testing market is projected to witness a CAGR of 8.17% during the forecast period 2024-2031, growing from USD 13.03 billion in 2023 to USD 24.42 billion in 2031. The market's growth is supported by the rising incidences of endocrine disorders, increasing awareness about preventive healthcare, and growing product launches by market players with enhanced features and patient convenience. In August 2023, the US Food and Drug Administration (FDA) listed the Mira Fertility Ovum Wand as an over-the-counter tool for tracking follicle-stimulating hormone (FSH) levels in urine. The wand can provide lab-accurate FSH levels for assessing fertility, predicting menopause, and supporting ovulation predictions.

Endocrine testing is essential for identifying abnormalities and imbalances in the endocrine system and assessing hormone levels for management and early detection of health conditions such as reproductive issues, diabetes, and thyroid disorders. Increasing investments by the healthcare sector to bolster the accessibility and affordability of these tests are expected to influence the market's expansion positively.

Furthermore, the rising awareness among the general population about endocrine disorders and the increasing efforts by various healthcare organizations to boost the accessibility of endocrine testing are providing lucrative growth opportunities to the market. Several healthcare organizations and government institutions are increasingly focusing on regular checkups for population groups that are at a higher risk of developing diabetes and thyroid disorders. Meanwhile, the general population is seeking regular health checkups to identify potential health issues on time due to increasing health consciousness. Additionally, the shift towards preventive healthcare is also propelling the demand for endocrine testing in various regions across the globe.

Increasing Prevalence of Endocrine Disorders Boosts Market Demand

Factors such as environmental influence, lifestyle changes, and genetic predisposition contribute significantly to endocrine disorders. These disorders also occur if the body cannot respond to hormones as it is supposed to. According to a National Center for Biotechnology Information (NCBI) study, the prevalence of endocrine disorders in adults in the United States is at least 5%. The rising cases of endocrine disorders are thus bolstering the reliance on endocrine testing to detect hormonal abnormalities and identify diseases.

The increasing incidences of hypothyroidism and diabetes, coupled with the increasing awareness about such conditions, is another major factor boosting the global endocrine testing market size.

Additionally, environmental factors and evolving lifestyles are also propelling the prevalence of endocrine disorders. Rising exposure to endocrine-disrupting chemicals, poor diet, stress, and sedentary habits have also been linked with the growing incidences of endocrine diseases. Endocrine-disrupting chemicals are usually found in a wide range of products, from pesticides to plastics, and have been shown to interfere with optimal hormone functioning, resulting in conditions such as reproductive health issues and thyroid imbalance.

Development of Novel Technologies Supports Market Expansion

The development of novel products and technologies plays a vital role in expanding the global endocrine testing market. Advancements in monitoring and diagnostics allow the development of endocrine testing solutions that deliver more reliable and faster results, allowing healthcare professionals to diagnose complex hormonal issues effectively. The growing demand for efficient, accessible, and patient-friendly testing solutions is thus propelling the growth of the endocrine testing market. Healthcare companies and startups across the globe are actively working on launching newer endocrine testing devices.

In July 2023, Mylab Discovery Solutions Pvt. Ltd., a Pune-based biotech startup, launched the Mybox+ diagnostic device with a broad range of tests, including biomarker (CRP, D-Dimer), cardiac marker (Troponin), and thyroid panel (T-3, T-4, TSH). Introducing this solution and the Dry Luminescence technology shows a transformative step in diagnostics and empowers clinics and labs by allowing them to provide a wide range of tests, thus aiding them in improving patient care. This technology offers a game-changing solution for clinics and small laboratories that have previously faced limitations in performing various tests and had to rely on larger facilities, often resulting in increased costs and delayed results. Thus, developing novel technologies improves patient convenience and positively influences the expansion of the endocrine testing market.

Thyroid Stimulating Hormone (TSH) Test Accounts for Significant Market Share

The growth of the segment is supported by increasing awareness about the importance of early detection of thyroid disorders and the rising prevalence of such conditions. According to the estimates of the American Thyroid Association, approximately 20 million Americans have some type of thyroid disease. Thyroid testing focuses on checking T3, T4, and TSH levels. It is one of the most performed endocrine tests across the globe as the incidences of hyperthyroidism and hypothyroidism increase. The growing efforts by the leading market players to ensure the availability of accurate and user-friendly testing devices and home-use testing kits are also expected to bolster the segment's expansion and provide lucrative growth opportunities to the global endocrine testing market.

Additionally, the increasing integration of TSH tests in preventive healthcare practices, particularly in population groups that are at high risk or have a history of thyroid disorders, is also propelling the segment's growth. Early detection can aid healthcare providers in preventing the occurrence of serious complications, including fertility issues, metabolic problems, and cardiovascular diseases. Furthermore, a rising number of healthcare professionals are advocating regular TSH testing for patients showing non-specific symptoms such as weight changes, fatigue, and depression, further bolstering the test's demand.

North America Holds Major Market Share

The rapid expansion of the market in the region can be attributed to the expansion of the population, growth of the healthcare sector, introduction of proactive government measures and policies, increasing the burden of different diseases, and rising awareness among the patient population. The strong presence of leading market players and the easy availability of healthcare services are also positively influencing the market's expansion.

The rising cases of endocrine-related diseases such as thyroid cancer are also bolstering the market demand in North America. According to the estimates of the American Cancer Society, approximately 44,020 new cases of thyroid cancer are expected to be reported in the United States in 2024. Additionally, the presence of various organizations that monitor and screen thyroid dysfunction and are devoted to thyroid biology and prevention and treatment of various thyroid diseases also provides lucrative growth opportunities to the market.

Furthermore, the rising cases of diabetes and the increasing requirement for insulin testing are also expected to bolster the market's demand. As per the estimates of the Centers for Disease Control and Prevention, approximately 38 million individuals in the United States have diabetes.

Future Market Scenario (2024-2031F)

As per the global endocrine testing market analysis, the demand is expected to be driven by increasing emphasis on preventive healthcare, rapid advancements in diagnostic technologies, and increasing incidences of endocrine disorders. Additionally, the rising requirement for point-of-care testing and increasing integration of machine learning and artificial intelligence in diagnostics is expected to drive innovation and propel the global endocrine testing market growth. The increasing prevalence of various endocrine disorders, including thyroid disorders and diabetes, in combination with supportive reimbursement policies, is expected to drive the global endocrine testing market demand. As per the estimates by the International Diabetes Federation (IDF), approximately 783 million individuals across the globe will be living with diabetes by 2045.

Additionally, the rapid expansion of the population and increasing burden on the healthcare sector are also expected to provide lucrative growth opportunities for the market. Endocrine testing is usually deployed in cases where doctors suspect that the patient might have an endocrine disorder or receive abnormal results for other function studies. The blood tests aid in confirming or eliminating suspicions and allow the identification of the root cause of the problem.

Key Players Landscape and Outlook

Various healthcare companies across the globe are actively working on delivering testing solutions that provide rapid and precise results. These companies are also actively working to raise funding to advance endocrine testing technologies. In April 2023, Eli Health raised USD 3.6 million to advance women's health with the help of saliva-based hormone monitoring technology. Hormone fluctuations affect a wide range of conditions, and women experience symptoms through puberty and post-menopause. Despite the accessibility of at-home hormone urine tests, the only options available outside of fertility are not appropriate for long-term and high-frequency testing due to high waiting time and costs. Thus, Eli Health is working on providing real-time insights into hormone levels with the help of saliva testing that can be tracked over time, unlike the traditional tests or methods that can only provide an isolated snapshot of hormone levels.

Similarly, in May 2022, a Berlin-based startup raised approximately USD 10.13 million (€9.3 million) in funding to expand their hormone tracking technology. Their biosensor mini lab allows women to discover their progesterone levels regularly by performing a saliva test. Such funding is expected to aid healthcare companies in bridging the gaps in women's health.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Endocrine Testing Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. Thyroid Stimulating Hormone (TSH) Test
      • 4.2.1.2. Insulin Test
      • 4.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 4.2.1.4. Prolactin Test
      • 4.2.1.5. Luteinizing Hormone (LH) Test
      • 4.2.1.6. Progesterone Test
      • 4.2.1.7. Others
    • 4.2.2. By Technology
      • 4.2.2.1. Tandem Mass Spectrometry
      • 4.2.2.2. Immunoassay
      • 4.2.2.3. Monoclonal and Polyclonal Antibody Technologies
      • 4.2.2.4. Sensor Technology
      • 4.2.2.5. Clinical Chemistry
      • 4.2.2.6. Others
    • 4.2.3. By End-user
      • 4.2.3.1. Hospitals
      • 4.2.3.2. Clinical Laboratories
      • 4.2.3.3. Diagnostic Centers
      • 4.2.3.4. Ambulatory Care Centers
      • 4.2.3.5. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Test Type
    • 4.3.2. By Technology
    • 4.3.3. By End-user
    • 4.3.4. By Region

5. North America Endocrine Testing Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Test Type
      • 5.2.1.1. Thyroid Stimulating Hormone (TSH) Test
      • 5.2.1.2. Insulin Test
      • 5.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 5.2.1.4. Prolactin Test
      • 5.2.1.5. Luteinizing Hormone (LH) Test
      • 5.2.1.6. Progesterone Test
      • 5.2.1.7. Other
    • 5.2.2. By Technology
      • 5.2.2.1. Tandem Mass Spectrometry
      • 5.2.2.2. Immunoassay
      • 5.2.2.3. Monoclonal and Polyclonal Antibody Technologies
      • 5.2.2.4. Sensor Technology
      • 5.2.2.5. Clinical Chemistry
      • 5.2.2.6. Others
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Clinical Laboratories
      • 5.2.3.3. Diagnostic Centers
      • 5.2.3.4. Ambulatory Care Centers
      • 5.2.3.5. Others
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Endocrine Testing Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Test Type
          • 5.3.1.2.1.1. Thyroid Stimulating Hormone (TSH) Test
          • 5.3.1.2.1.2. Insulin Test
          • 5.3.1.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
          • 5.3.1.2.1.4. Prolactin Test
          • 5.3.1.2.1.5. Luteinizing Hormone (LH) Test
          • 5.3.1.2.1.6. Progesterone Test
          • 5.3.1.2.1.7. Others
        • 5.3.1.2.2. By Technology
          • 5.3.1.2.2.1. Tandem Mass Spectrometry
          • 5.3.1.2.2.2. Immunoassay
          • 5.3.1.2.2.3. Monoclonal and Polyclonal Antibody Technologies
          • 5.3.1.2.2.4. Sensor Technology
          • 5.3.1.2.2.5. Clinical Chemistry
          • 5.3.1.2.2.6. Others
        • 5.3.1.2.3. By End-user
          • 5.3.1.2.3.1. Hospitals
          • 5.3.1.2.3.2. Clinical Laboratories
          • 5.3.1.2.3.3. Diagnostic Centers
          • 5.3.1.2.3.4. Ambulatory Care Centers
          • 5.3.1.2.3.5. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Endocrine Testing Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Endocrine Testing Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Endocrine Testing Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Endocrine Testing Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Abbott Laboratories
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. bioMerieux SA
    • 20.3.3. Siemens Healthineers AG
    • 20.3.4. Thermo Fisher Scientific Inc.
    • 20.3.5. Agilent Technologies, Inc.
    • 20.3.6. F. Hoffmann-La Roche Ltd
    • 20.3.7. AB Sciex Pte. Ltd.
    • 20.3.8. DiaSorin S.p.A.
    • 20.3.9. Quest Diagnostics Incorporated
    • 20.3.10. Danaher Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 3. Global Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 4. Global Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Endocrine Testing Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 8. North America Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 9. North America Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 13. United States Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 14. United States Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 17. Canada Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 18. Canada Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 21. Mexico Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 22. Mexico Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 25. Europe Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 26. Europe Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 30. Germany Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 31. Germany Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 34. France Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 35. France Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 38. Italy Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 39. Italy Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 42. United Kingdom Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 43. United Kingdom Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 46. Russia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 47. Russia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 50. Netherlands Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 51. Netherlands Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 54. Spain Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 55. Spain Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 58. Turkey Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 59. Turkey Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 62. Poland Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 63. Poland Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 66. South America Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 67. South America Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 71. Brazil Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 72. Brazil Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 75. Argentina Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 76. Argentina Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 79. Asia-Pacific Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 80. Asia-Pacific Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 82. India Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 84. India Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 85. India Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 88. China Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 89. China Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 92. Japan Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 93. Japan Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 96. Australia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 97. Australia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 100. Vietnam Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 101. Vietnam Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 104. South Korea Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 105. South Korea Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 108. Indonesia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 109. Indonesia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 112. Philippines Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 113. Philippines Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 116. Middle East & Africa Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 117. Middle East & Africa Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 121. Saudi Arabia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 122. Saudi Arabia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 125. UAE Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 126. UAE Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 129. South Africa Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 130. South Africa Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023